Dosing & Uses
Familial Chylomicronemia Syndrome
Pending FDA approval for familial chylomicronemia syndrome (FCS)
Next:
Pharmacology
Mechanism of Action
Blocks synthesis of apolipoprotein C-III (ApoC-III) resulting in decreased plasma triglycerides (TG)
ApoC-III affects TG metabolism by inhibiting lipoprotein lipase (LPL) activity and by interfering with receptor-mediated uptake of TG-rich lipoprotein (TRL) by the liver
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
